TP53 and gastric cancer: Our immunohistochemical observations also support this notion because type II AEGs with an “atrophic” background showed immunophenotypes similar to those of the combined type III AEG plus GC group, whereas those with a “non‐atrophic” background more frequently showed MMR deficiency, TP53 overexpression, and negativity for intestinal phenotypic markers, as compared to the combined type III AEGs plus GCs group.